Zedira receives funding for the development of transglutaminase inhibitors

01-Dec-2016 - Zedira announced today that the BMBF will grant additional 1.5 million Euros funding to the company within the highly competitive SME-Innovative program over the next three years. The aim of the project is for Zedira to develop small molecule tissue transglutaminase inhibitors that are orally ...

Cooperation between Zedira and Cardiff University

Transglutaminase 6 is the focus of new research into ataxia

21-Oct-2015 - Zedira and Cardiff University have initiated a joint project addressing questions regarding the role of an enzyme called transglutaminase 6 in the pathophysiology of neurodegenerative diseases. This work builds on and extends previous successful collaborations between the two partners in the ...

Zedira, Dr. Falk Pharma and the University of Mainz Hospital receive subsidy funding for clinical development of a celiac disease drug

Flagship project of the Ci3 leading-edge cluster

20-Oct-2015 - The consortium consisting of Zedira, Dr. Falk Pharma and Prof. Schuppan of the Institute of Translational Immunology and the Department of Medicine at the Johannes Gutenberg University in Mainz has announced that their collaboration on drug development of celiac disease is being further supported ...

Zedira, Dr. Falk Pharma and the University of Mainz Hospital are to receive subsidy funding

27-Jun-2012 - The consortium consisting of Zedira, Dr. Falk Pharma and Prof. Schuppan of the medical department at the Johannes Gutenberg University in Mainz has announced that their collaboration on drug development of celiac disease is being subsidised under the CI3 excellence cluster of the German Federal ...

Zedira licenses ZED-101 for celiac disease therapy to Dr. Falk Pharma in Europe

30-Nov-2011 - Zedira GmbH today announced that it has licensed exclusive rights to develop and market ZED-101 in Europe to Dr. Falk Pharma GmbH, Germany. ZED-101 is a new chemical entity blocking specifically tissue transglutaminase. Tissue transglutaminase is the key player in pathogenesis of celiac ...

Zedira Presents Clinical Candidate for Celiac Disease Therapy

24-Sep-2009 - In course of the Chicago Celiac Disease Conference preclinical data has been presented supporting the selection of Zedira’s novel Transglutaminase blocker ZED-101 as clinical candidate for the treatment of celiac disease. Blocking tissue transglutaminase is a promising therapeutic option in ...

Zedira receives a research grant of 750,000 Euros for the development of novel compounds for thromboprophylaxis

06-Feb-2009 - As part of the funding program "KMU-innovativ", Zedira will receive a research grant of 750,000 Euros over a period of two years from the Federal Ministry of Education and Research. Zedira plans to expand its drug development pipeline based on proprietary inhibitors that specifically target blood ...